文献速递血栓与止血

重型COVID-19中凝血因子V活性显著升高与静脉血栓栓塞相关

Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism.
PubMed 文献 · Am J Hematol · 2020-09-18

在102例连续住院的COVID-19患者中,凝血因子V活性中位数150 IU/dL,显著高于同期对照的105 IU/dL(P < .001),且为所研究参数中与COVID-19关联最强者。因子V活性>150 IU/dL者深静脉血栓或肺栓塞发生率为33%(16/49),高于≤150 IU/dL者的13%(7/53)(P = .03)。因子V后续下降与DIC进展和死亡相关。

要点

  • 重型COVID-19患者凝血因子V活性中位数150 IU/dL,显著高于同期对照的105 IU/dL。
  • 因子V活性>150 IU/dL者DVT/PE发生率为33%(16/49),高于≤150 IU/dL者的13%(7/53)。
  • 因子V活性与SARS-CoV-2载量的关联呈性别依赖性,因子V后续下降与DIC进展和死亡相关。

核心结论

  • 重型COVID-19中存在凝血因子V活性的显著扰动,其与SARS-CoV-2疾病生物学和临床结局相关,并提名作为候选生物标志物以研究指导COVID-19抗凝治疗。

研究设计与样本

  • 检测102例连续住院COVID-19患者的凝血因子V、VIII和X活性,并与同期SARS-CoV-2阴性对照(n = 17)和历史大流行前对照(n = 260-478)进行分析。

主要发现

  • 队列代表重型COVID-19,呼吸机使用率92%,导管相关血栓47%,深静脉血栓或肺栓塞23%,死亡率22%。
  • COVID-19患者凝血因子V活性中位数150 IU/dL(范围34-248 IU/dL),高于同期对照的105 IU/dL(范围22-161 IU/dL)(P < .001),为所研究参数(包括因子VIII、纤维蛋白原和D-二聚体)中与COVID-19关联最强者。
  • COVID-19患者中因子V活性>150 IU/dL者DVT/PE发生率为33%(16/49),高于因子V活性≤150 IU/dL者的13%(7/53)(P = .03)。
  • 在该重型COVID-19队列中,因子V活性与SARS-CoV-2载量的关联呈性别依赖性。
  • 因子V后续下降与向DIC进展和死亡相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coagulopathy causes morbidity and mortality in patients with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Yet, the mechanisms are unclear and biomarkers are limited. Early in the pandemic, we observed markedly elevated factor V activity in a patient with COVID-19, which led us to measure factor V, VIII, and X activity in a cohort of 102 consecutive inpatients with COVID-19. Contemporaneous SARS-CoV-2-negative controls (n = 17) and historical pre-pandemic controls (n = 260-478) were also analyzed. This cohort represents severe COVID-19 with high rates of ventilator use (92%), line clots (47%), deep vein thrombosis or pulmonary embolism (DVT/PE) (23%), and mortality (22%). Factor V activity was significantly elevated in COVID-19 (median 150 IU/dL, range 34-248 IU/dL) compared to contemporaneous controls (median 105 IU/dL, range 22-161 IU/dL) (P < .001)-the strongest association with COVID-19 of any parameter studied, including factor VIII, fibrinogen, and D-dimer. Patients with COVID-19 and factor V activity >150 IU/dL exhibited significantly higher rates of DVT/PE (16/49, 33%) compared to those with factor V activity ≤150 IU/dL (7/53, 13%) (P = .03). Within this severe COVID-19 cohort, factor V activity associated with SARS-CoV-2 load in a sex-dependent manner. Subsequent decreases in factor V were linked to progression toward DIC and mortality. Together, these data reveal marked perturbations of factor V activity in severe COVID-19, provide links to SARS-CoV-2 disease biology and clinical outcomes, and nominate a candidate biomarker to investigate for guiding anticoagulation therapy in COVID-19.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Stefely JA, Christensen BB, Gogakos T, et al. Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism. Am J Hematol. 2020. PMID: 32833259. doi:10.1002/ajh.25979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。